Literature DB >> 32146948

Laparoscopic Hernia Repair and Fundoplication for Gastroesophageal Reflux Disease.

Steven R DeMeester1.   

Abstract

Antireflux surgery is challenging, and has become even more challenging with the introduction of alternative endoscopic and laparoscopic options for patients with gastroesophageal reflux disease (GERD). The Nissen fundoplication remains the gold standard for the durable relief of GERD symptoms and esophagitis. All antireflux procedures have a failure rate, and it is important to minimize factors that are associated with failure. The selection of patients for antireflux surgery as well as the choice of the procedure requires a thorough understanding of esophageal physiology and the pros and cons of various options.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antireflux surgery; Fundoplication; Hiatal hernia

Year:  2020        PMID: 32146948     DOI: 10.1016/j.giec.2019.12.007

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  3 in total

1.  Augmentation of Hiatal Repair with the Ligamentum Teres Hepatis for Intrathoracic Gastric Migration After Bariatric Surgery.

Authors:  Alexander Runkel; Oliver Scheffel; Goran Marjanovic; Sonja Chiappetta; Norbert Runkel
Journal:  Obes Surg       Date:  2021-01-06       Impact factor: 4.129

2.  Fundoplication after lung transplantation in patients with systemic sclerosis-related end-stage lung disease.

Authors:  Miguel M Leiva-Juárez; Andreacarola Urso; Joseph Costa; Bryan P Stanifer; Joshua R Sonett; Luke Benvenuto; Megan Aversa; Hilary Robbins; Lori Shah; Selim Arcasoy; Frank D'Ovidio
Journal:  J Scleroderma Relat Disord       Date:  2021-05-25

3.  A new technique for treating hiatal hernia with gastroesophageal reflux disease: the laparoscopic total left-side surgical approach.

Authors:  Zhi Zheng; Xiaoye Liu; Chenglin Xin; Weitao Zhang; Yan Gao; Na Zeng; Mengyi Li; Jun Cai; Fandong Meng; Dong Liu; Jie Zhang; Jie Yin; Jun Zhang; Zhongtao Zhang
Journal:  BMC Surg       Date:  2021-10-09       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.